Pemvidutide

Pemvidutide, formerly ALT-801, is a peptide GLP-1/glucagon dual agonist. Altimmune’s original filing describes obesity and liver-disease research; the current pipeline includes Phase 3 MASH development and additional alcohol-related programs.

Mazdutide and survodutide are also peptide dual agonists, not non-peptide alternatives. Structural class does not establish equivalent efficacy, a tolerability ranking or interchangeability.

Combined receptor activity is intended to influence metabolic and hepatic pathways. The IMPACT trial tested biopsy-defined MASH and fibrosis outcomes rather than relying solely on a mechanistic claim that more fat oxidation improves liver disease.

A liver-fat measurement, histologic MASH resolution and fibrosis improvement are different endpoints. Each should retain its time point and analysis rather than being collapsed into a general claim that pemvidutide treats every form of fatty liver disease.

In Altimmune’s company-reported MOMENTUM results, 391 participants without diabetes were randomized for 48 weeks. Reported mean weight losses were 10.3%, 11.2% and 15.6% at 1.2, 1.8 and 2.4 mg versus 2.2% placebo. These are company-reported trial results, not a 12–16-week forecast or a direct comparison with another medicine.

The peer-reviewed IMPACT abstract reports 212 randomized patients with biopsy-confirmed MASH and F2/F3 fibrosis. At week 24, MASH resolution without worsening fibrosis was reported in 58% and 52% at 1.2 and 1.8 mg versus 20% placebo. Fibrosis improvement without worsening MASH was 33% and 36% versus 28%; those comparisons were not significant (P=0.59 and 0.27).

IMPACT’s MASH-resolution finding is a meaningful positive signal alongside the neutral fibrosis result. Neither should erase the other.

The PERFORMA registry lists a recruiting Phase 3 MASH study with no posted results, last updated September 23, 2026. Altimmune’s pipeline also describes AUD and alcohol-associated liver-disease work. Registration, enrollment milestones and Fast Track or Breakthrough designations are separate from demonstrated results and approval.

IMPACT used 1.2 or 1.8 mg once weekly without dose titration. The MOMENTUM report describes weekly 1.2, 1.8 and 2.4 mg; the lower amounts had no titration and 2.4 mg used a short four-week escalation. These studies do not establish a standard twice-weekly 3–8 mg regimen.

Altimmune currently states that pemvidutide remains investigational and is not approved by FDA or another regulatory authority. Trial amounts and a recruiting registry are not a marketed prescription label or a guaranteed commercial-access date.

In IMPACT, adverse events were reported in 78% and 81% of active groups versus 67% placebo, mostly mild or moderate. Adverse-event discontinuation occurred in zero of 41, one of 85 and two of 86 participants, respectively. This describes the actual study rather than an assumed class-wide side-effect frequency.

The company-reported MRI body-composition substudy is a useful early signal, but it is not a head-to-head muscle-preservation trial or proof that all weight loss is fat. Safety, body composition and clinical outcomes require their own follow-up; no universal contraindication list should be invented from another drug’s label.

Editorial update: October 27, 2026. The original IMPACT indexed abstract, scoped MOMENTUM and body-composition passages in Altimmune’s filing, current sponsor pipeline and PERFORMA registry were read. The original conference full page was inaccessible; company-reported findings are attributed. Not all full papers were obtained. This is an editorial source check, not clinician review or a completed whole-family review. Read a key primary source.